Reviva Pharmaceuticals (RVPH)
Market Price (4/11/2026): $0.7621 | Market Cap: $4.5 MilSector: Health Care | Industry: Biotechnology
Reviva Pharmaceuticals (RVPH)
Market Price (4/11/2026): $0.7621Market Cap: $4.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -310% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -130%, 3Y Excs Rtn is -165% | Penny stockMkt Price is 0.8 Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -444% High stock price volatilityVol 12M is 158% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 31% Key risksRVPH key risks include [1] a make-or-break dependence on the clinical and regulatory success of its sole late-stage drug candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -310% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -130%, 3Y Excs Rtn is -165% |
| Penny stockMkt Price is 0.8 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -444% |
| High stock price volatilityVol 12M is 158% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 31% |
| Key risksRVPH key risks include [1] a make-or-break dependence on the clinical and regulatory success of its sole late-stage drug candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Reviva Pharmaceuticals (RVPH) stock has lost about 85% since 12/31/2025 because of the following key factors:
1. Regulatory Delay and Increased Development Costs for Lead Candidate.
Reviva Pharmaceuticals announced on December 23, 2025, and reiterated in its March 30, 2026, full-year report, that the FDA recommended a second Phase 3 clinical trial (RECOVER-2) for brilaroxazine in schizophrenia to generate additional efficacy and safety data prior to a New Drug Application (NDA) submission. This regulatory feedback significantly delays the potential commercialization of their lead product candidate, as the initiation of RECOVER-2 is planned for mid-2026 with completion targeted for Q4 2027, extending the timeline to market and increasing development expenditures.
2. Significant Share Dilution from Public Offerings.
The company engaged in dilutive capital raises to fund its operations and the additional clinical trial requirements. In March 2026, Reviva completed a public equity offering, raising gross proceeds of $10.0 million. This follows earlier at-the-market offerings, and the company's 2025 annual report indicated that total shares outstanding grew by 462.9% over the past year, significantly diluting existing shareholders.
Show more
1. Regulatory Delay and Increased Development Costs for Lead Candidate.
Reviva Pharmaceuticals announced on December 23, 2025, and reiterated in its March 30, 2026, full-year report, that the FDA recommended a second Phase 3 clinical trial (RECOVER-2) for brilaroxazine in schizophrenia to generate additional efficacy and safety data prior to a New Drug Application (NDA) submission. This regulatory feedback significantly delays the potential commercialization of their lead product candidate, as the initiation of RECOVER-2 is planned for mid-2026 with completion targeted for Q4 2027, extending the timeline to market and increasing development expenditures.
2. Significant Share Dilution from Public Offerings.
The company engaged in dilutive capital raises to fund its operations and the additional clinical trial requirements. In March 2026, Reviva completed a public equity offering, raising gross proceeds of $10.0 million. This follows earlier at-the-market offerings, and the company's 2025 annual report indicated that total shares outstanding grew by 462.9% over the past year, significantly diluting existing shareholders.
Show more
Stock Movement Drivers
Fundamental Drivers
The -86.2% change in RVPH stock from 12/31/2025 to 4/10/2026 was primarily driven by a -38.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 4102026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.58 | 0.77 | -86.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 4 | 6 | -38.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 4/10/2026| Return | Correlation | |
|---|---|---|
| RVPH | -86.2% | |
| Market (SPY) | -5.4% | 29.8% |
| Sector (XLV) | -4.8% | 29.0% |
Fundamental Drivers
The -89.5% change in RVPH stock from 9/30/2025 to 4/10/2026 was primarily driven by a -57.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 4102026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.37 | 0.77 | -89.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 6 | -57.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 4/10/2026| Return | Correlation | |
|---|---|---|
| RVPH | -89.5% | |
| Market (SPY) | -2.9% | 22.1% |
| Sector (XLV) | 6.3% | 15.1% |
Fundamental Drivers
The -96.0% change in RVPH stock from 3/31/2025 to 4/10/2026 was primarily driven by a -71.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312025 | 4102026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.08 | 0.77 | -96.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 6 | -71.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2025 to 4/10/2026| Return | Correlation | |
|---|---|---|
| RVPH | -96.0% | |
| Market (SPY) | 16.3% | 17.3% |
| Sector (XLV) | 2.3% | 19.1% |
Fundamental Drivers
The -99.1% change in RVPH stock from 3/31/2023 to 4/10/2026 was primarily driven by a -81.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312023 | 4102026 | Change |
|---|---|---|---|
| Stock Price ($) | 83.80 | 0.77 | -99.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 6 | -81.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2023 to 4/10/2026| Return | Correlation | |
|---|---|---|
| RVPH | -99.1% | |
| Market (SPY) | 63.3% | 11.1% |
| Sector (XLV) | 19.1% | 13.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RVPH Return | -67% | 47% | 21% | -65% | -85% | -85% | -100% |
| Peers Return | -28% | -14% | 55% | -26% | 223% | 16% | 169% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| RVPH Win Rate | 33% | 42% | 33% | 25% | 33% | 50% | |
| Peers Win Rate | 47% | 50% | 48% | 43% | 60% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| RVPH Max Drawdown | -69% | -79% | -16% | -87% | -85% | -88% | |
| Peers Max Drawdown | -41% | -56% | -29% | -42% | -30% | -19% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AXSM, NBIX, NERV, RLMD, VNDA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)
How Low Can It Go
| Event | RVPH | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -93.7% | -25.4% |
| % Gain to Breakeven | 1481.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -33.3% | -33.9% |
| % Gain to Breakeven | 50.0% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -7.1% | -19.8% |
| % Gain to Breakeven | 7.7% | 24.7% |
| Time to Breakeven | 404 days | 120 days |
Compare to AXSM, NBIX, NERV, RLMD, VNDA
In The Past
Reviva Pharmaceuticals's stock fell -93.7% during the 2022 Inflation Shock from a high on 1/19/2021. A -93.7% loss requires a 1481.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Reviva Pharmaceuticals (RVPH)
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
AI Analysis | Feedback
- Think of it as a smaller, clinical-stage version of a large pharmaceutical company such as Eli Lilly or Pfizer, with its main focus on getting a schizophrenia drug through the final stages of clinical trials.
- It's like a biotech startup aspiring to be the next Amgen or Gilead, with its future largely depending on the success of its advanced schizophrenia drug and other pipeline candidates.
AI Analysis | Feedback
- RP5063: A drug candidate in Phase III clinical trials for schizophrenia, also being developed for bipolar disorder, major depressive disorder, ADHD, dementia-related psychosis, Parkinson's disease psychosis, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.
- RP1208: A drug candidate in pre-clinical development studies for the treatment of depression and obesity.
AI Analysis | Feedback
Reviva Pharmaceuticals Holdings, Inc. (RVPH) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation therapeutics. As described, its lead product candidate, RP5063, is in Phase III clinical trials, and other candidates like RP1208 are in pre-clinical development.
Due to its current stage as a clinical-stage company, Reviva Pharmaceuticals does not yet have commercialized products available for sale on the market. Therefore, the company does not have major customers in the traditional sense of selling therapeutics to other companies (such as distributors, hospitals, or pharmacies) or directly to individuals (patients).
Its primary activities involve research and development, conducting clinical trials, and advancing its drug candidates through the regulatory approval process. Potential future revenue streams and "customers" would emerge upon successful commercialization of its product candidates, either directly or through licensing agreements with other pharmaceutical companies.
AI Analysis | Feedback
nullAI Analysis | Feedback
Laxminarayan Bhat, PhD, Founder, President and Chief Executive OfficerDr. Bhat founded Reviva Pharmaceuticals in 2006. He has over 20 years of experience in drug discovery and development, having held research positions at XenoPort, ARYx Therapeutics, and Higuchi Biosciences Center prior to founding Reviva. He received a global post-doctoral training at the University of Kansas, USA, the Georg-August-Universität, Göttingen, Germany, and the Université du Maine, France. In 1995, he was selected for the Alexander von Humboldt fellowship. Dr. Bhat has authored over 25 research papers and is an inventor on over 100 granted patents.
Narayan Prabhu, Chief Financial Officer
Mr. Prabhu brings over 20 years of finance leadership and experience in biotechnology, life sciences, and information technology. Prior to Reviva, he served as the Chief Financial Officer at Sony Biotechnology, where he led the global expansion of the company and commercialized several products. Mr. Prabhu also served as an M&A Controller at Cisco, leading the finance acquisition and integration of more than a dozen companies, including multi-billion-dollar acquisitions in Network Security and Software. He is a Certified Public Accountant and holds a Bachelor of Science degree in Accounting and Finance from Indiana University at Bloomington – Kelley School of Business and an MBA from the University of California at Berkeley – Haas School of Business.
Seema Bhat, Vice President, Program and Portfolio
Seema Bhat has extensive experience in the pharmaceutical industry. She has been with Reviva Pharmaceuticals since at least 2011, serving as Manager of R&D Programs and IP from February 2011 to 2014, and then as Director of R&D Programs and IP from March 2014 to 2019, before becoming Vice President of Program and Portfolio in March 2020. Prior to joining Reviva Pharmaceuticals, she worked as a Medicinal Chemist at Genentech from 2008 to 2010. Seema Bhat holds a Bachelor's and Master's degree in Organic Chemistry from Central University in NEHU, India, and completed a program in Clinical Trials Design and Management at the University of California, Santa Cruz.
AI Analysis | Feedback
Key Risks for Reviva Pharmaceuticals (RVPH)
- Clinical Trial Success and Regulatory Approval: Reviva Pharmaceuticals' primary risk stems from the uncertain outcome of its clinical trials and the subsequent regulatory approval process. The company's lead product candidate, brilaroxazine (RP5063), is in late-stage clinical development for schizophrenia. Despite positive data from its Phase III RECOVER-1 trial and an open-label extension study, the U.S. Food and Drug Administration (FDA) has recommended an additional Phase III trial (RECOVER-2) before a New Drug Application (NDA) submission. This significantly delays potential market entry and adds substantial risk, as success in clinical trials is not guaranteed, and regulatory approval is a complex and often unpredictable hurdle. The failure of brilaroxazine to achieve regulatory approval would have a severe negative impact on the company.
- Funding and Dilution: As a clinical-stage biopharmaceutical company with no current product revenue, Reviva Pharmaceuticals operates with a significant cash burn and has a limited cash runway. The recent FDA recommendation for an additional Phase III trial for brilaroxazine will necessitate substantial further investment, increasing the company's capital requirements. This almost certainly means the company will need to raise additional capital, likely through further equity offerings, which would lead to significant dilution for existing shareholders, a trend already observed with past financings. The ability to secure sufficient funding is critical for the continued development and potential commercialization of its drug candidates.
- Competition: Reviva Pharmaceuticals operates in highly competitive therapeutic areas, particularly for schizophrenia, where its lead candidate brilaroxazine is being developed. The global schizophrenia market already includes established pharmaceutical companies with approved products, such as Otsuka's Abilify and Johnson & Johnson's Caplyta, as well as other companies developing late-stage treatments. If approved, brilaroxazine would need to effectively differentiate itself and compete for market share against these existing and emerging therapies. Furthermore, the original patent for brilaroxazine is set to expire in 2030, which could expose the company to generic competition in the future.
AI Analysis | Feedback
nullAI Analysis | Feedback
Reviva Pharmaceuticals (RVPH) targets several significant addressable markets with its main product candidates, RP5063 and RP1208.
RP5063 Product Candidate:
- Schizophrenia: The global schizophrenia market was valued at approximately USD 9,480.4 million in 2023 and is projected to reach USD 15,236.9 million by 2034. Another estimate places the global market at USD 8.18 billion in 2024, with a projection to reach USD 11.19 billion by 2030. The United States market alone for schizophrenia was nearly USD 6 billion in 2024.
- Bipolar Disorder: The global bipolar disorder market size was valued at USD 4.88 billion in 2023 and is projected to grow to USD 7 billion by 2033. Another source indicates the global market was USD 5.02 billion in 2024, projected to reach USD 6.27 billion by 2033. The market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is expected to grow from USD 5.6 billion in 2024 to USD 9.4 billion in 2034.
- Major Depressive Disorder (MDD): The global market for Major Depressive Disorder treatment is anticipated to grow from USD 12,000 million in 2025 to USD 15,800 million by 2035. The global MDD market size reached approximately US$ 6.84 billion in 2024 and is expected to reach US$ 14.57 billion by 2033. In 2023, the 7MM market size was approximately USD 7,165 million.
- Attention–Deficit/Hyperactivity Disorder (ADHD): The global attention deficit hyperactivity disorder market size was valued at USD 15.8 billion in 2023 and is estimated to grow to USD 24.6 billion by 2032. Another report estimates the global ADHD therapeutics market was valued at USD 35.17 billion in 2024, with a projection to reach USD 76.96 billion by 2033.
- Behavioral and Psychotic Symptoms of Dementia or Alzheimer's Disease (Psychosis in Alzheimer's Disease): The market for psychosis in Parkinson's disease and Alzheimer's disease across the seven major markets (7MM) was valued at approximately USD 1.29 billion in 2023. The U.S. market for this condition was approximately USD 868 million in 2023.
- Parkinson's Disease Psychosis: The seven major Parkinson's disease psychosis markets reached a value of USD 526.1 million in 2024 and are expected to reach USD 694.3 million by 2035. The total Parkinson's disease psychosis market size in 7MM was approximately USD 665 million in 2023.
- Pulmonary Arterial Hypertension (PAH): The global pulmonary arterial hypertension market size is projected to reach approximately USD 13.50 billion by 2034, from USD 8.48 billion in 2025. Other estimates place the global market at USD 8.3 billion in 2024, growing to USD 13.9 billion by 2034. The U.S. pulmonary arterial hypertension market size was USD 2.43 billion in 2025 and is expected to reach around USD 3.90 billion by 2034.
- Idiopathic Pulmonary Fibrosis (IPF): The global idiopathic pulmonary fibrosis market size was valued at around USD 3,763.90 million in 2023 and is predicted to grow to approximately USD 6,804.23 million by 2032. Another source indicates the global market was USD 4.54 billion in 2024 and is projected to reach USD 9.23 billion by 2033. The total market size in the 7MM was approximately USD 3,300 million in 2023.
RP1208 Product Candidate:
- Depression: The global depression market is expected to increase from an estimated USD 9.9 billion in 2020 to over USD 13.3 billion by 2030. (Note: Major Depressive Disorder, as covered above, is a significant component of the broader depression market).
- Obesity: The global market for anti-obesity medications reached USD 6 billion on an annualized basis in early 2023 and could grow to USD 100 billion by 2030. The global obesity treatment market size was USD 15.74 billion in 2024 and is expected to reach around USD 98.26 billion by 2034. The U.S. obesity treatment market size was valued at USD 5.31 billion in 2024 and is expected to reach around USD 33.16 billion by 2034.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Reviva Pharmaceuticals (RVPH) over the next 2-3 years:
- Advancement and Potential Regulatory Approval of Brilaroxazine (RP5063) for Schizophrenia: The initiation of the RECOVER-2 Phase 3 trial in the first half of 2026, following the FDA's recommendation for additional efficacy and safety data, is a critical step. While this delays the New Drug Application (NDA) filing timeline to at least 2027, successful completion of this trial and subsequent regulatory approval in 2028 or beyond is the primary long-term revenue driver. Analysts project significant revenue for Reviva Pharmaceuticals starting in 2028, reflecting the market's expectation of brilaroxazine's potential entry for schizophrenia.
- Strategic Collaborations and Licensing Agreements: As a clinical-stage biopharmaceutical company, Reviva Pharmaceuticals emphasizes strategic collaborations and partnerships as a key component of its product development and growth plan. The company is actively seeking partnership opportunities, particularly for its preclinical programs. Such agreements, potentially for brilaroxazine across its various indications or for RP1208, could generate upfront payments and milestone-based revenue within the next 2-3 years, especially as financing is needed for ongoing clinical trials.
- Expansion of Brilaroxazine (RP5063) into Additional Therapeutic Areas: Reviva Pharmaceuticals is developing brilaroxazine for other indications beyond schizophrenia. The drug has received Orphan Drug Designation from the U.S. FDA for Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Arterial Hypertension (PAH). Furthermore, an Investigational New Drug (IND) application submission for a liposomal-gel formulation of brilaroxazine in psoriasis is expected by the second half of 2026. Progress in these additional therapeutic areas, especially those with orphan drug designations, could lead to further development opportunities, potential partnerships, and future revenue streams.
AI Analysis | Feedback
Share Issuance
- Reviva Pharmaceuticals completed public offerings in June and September 2025, raising approximately $10 million and $9 million in gross proceeds, respectively, through the issuance of common stock and accompanying warrants.
- The company generated approximately $6.7 million in net proceeds from the exercise of common stock warrants between October 1, 2025, and December 16, 2025.
- Stockholders approved an increase in authorized common stock to 515 million in December 2025, and a 1-for-20 reverse stock split was enacted on March 5, 2026, to address Nasdaq bid-price compliance.
Inbound Investments
- In June 2025, Reviva Pharmaceuticals raised approximately $10 million in gross proceeds from a public offering involving existing and new healthcare-focused institutional investors.
- Another public offering in September 2025 generated approximately $9 million in gross proceeds, also with participation from institutional investors.
- The company received approximately $6.7 million in net proceeds from the exercise of warrants by investors between October and December 2025.
Capital Expenditures
- Reviva Pharmaceuticals has reported consistently minimal or zero capital expenditures on physical assets over the last 3-5 years.
- As a clinical-stage biopharmaceutical company, the company's primary "investments" are in research and development activities, such as the projected $60 million for the RECOVER-2 trial, which are typically expensed rather than capitalized.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Reviva Pharmaceuticals Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to RVPH.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 7.25 |
| Mkt Cap | 0.5 |
| Rev LTM | 108 |
| Op Inc LTM | -40 |
| FCF LTM | -35 |
| FCF 3Y Avg | -33 |
| CFO LTM | -35 |
| CFO 3Y Avg | -33 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 21.4% |
| Rev Chg 3Y Avg | 24.3% |
| Rev Chg Q | 28.3% |
| QoQ Delta Rev Chg LTM | 6.6% |
| Op Mgn LTM | -26.5% |
| Op Mgn 3Y Avg | -32.5% |
| QoQ Delta Op Mgn LTM | 1.6% |
| CFO/Rev LTM | -14.6% |
| CFO/Rev 3Y Avg | -17.3% |
| FCF/Rev LTM | -14.7% |
| FCF/Rev 3Y Avg | -17.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.5 |
| P/S | 4.5 |
| P/EBIT | -1.5 |
| P/E | -1.1 |
| P/CFO | -4.2 |
| Total Yield | -31.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -33.3% |
| D/E | 0.0 |
| Net D/E | -0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -11.4% |
| 3M Rtn | 1.8% |
| 6M Rtn | 41.2% |
| 12M Rtn | 81.6% |
| 3Y Rtn | 81.7% |
| 1M Excs Rtn | -12.0% |
| 3M Excs Rtn | 3.8% |
| 6M Excs Rtn | 40.2% |
| 12M Excs Rtn | 41.7% |
| 3Y Excs Rtn | 46.6% |
Price Behavior
Price Behavior
| Market Price | $0.77 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/18/2018 | |
| Distance from 52W High | -96.6% | |
| 50 Days | 200 Days | |
| DMA Price | $3.27 | $7.88 |
| DMA Trend | down | down |
| Distance from DMA | -76.4% | -90.2% |
| 3M | 1YR | |
| Volatility | 158.7% | 158.4% |
| Downside Capture | 5.12 | 2.26 |
| Upside Capture | -95.23 | -9.89 |
| Correlation (SPY) | 28.8% | 17.9% |
RVPH Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 4.72 | 4.19 | 3.59 | 3.15 | 1.47 | 0.98 |
| Up Beta | 2.39 | 4.81 | 3.07 | 0.22 | 1.06 | 1.19 |
| Down Beta | -4.23 | -0.16 | 3.02 | 5.04 | 1.90 | 1.49 |
| Up Capture | 64% | 22% | -32% | 15% | -28% | -6% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 7 | 12 | 23 | 53 | 111 | 337 |
| Down Capture | 814% | 537% | 435% | 273% | 170% | 109% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 15 | 30 | 40 | 73 | 139 | 391 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RVPH | |
|---|---|---|---|---|
| RVPH | -92.8% | 158.1% | -0.75 | - |
| Sector ETF (XLV) | 12.3% | 16.8% | 0.52 | 17.5% |
| Equity (SPY) | 31.2% | 17.3% | 1.47 | 18.5% |
| Gold (GLD) | 60.1% | 27.8% | 1.69 | 11.2% |
| Commodities (DBC) | 29.8% | 16.6% | 1.58 | 3.8% |
| Real Estate (VNQ) | 21.3% | 15.2% | 1.07 | 15.6% |
| Bitcoin (BTCUSD) | -5.7% | 43.7% | -0.01 | 26.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RVPH | |
|---|---|---|---|---|
| RVPH | -63.0% | 133.3% | -0.11 | - |
| Sector ETF (XLV) | 6.3% | 14.6% | 0.25 | 10.2% |
| Equity (SPY) | 11.1% | 17.0% | 0.50 | 10.8% |
| Gold (GLD) | 22.1% | 17.8% | 1.02 | 4.7% |
| Commodities (DBC) | 11.8% | 18.8% | 0.52 | 3.8% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 7.8% |
| Bitcoin (BTCUSD) | 4.0% | 56.5% | 0.29 | 11.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RVPH | |
|---|---|---|---|---|
| RVPH | -42.5% | 110.8% | -0.15 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 7.1% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 7.7% |
| Gold (GLD) | 14.2% | 15.9% | 0.74 | 3.6% |
| Commodities (DBC) | 8.6% | 17.6% | 0.41 | 3.3% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.22 | 5.6% |
| Bitcoin (BTCUSD) | 67.4% | 66.9% | 1.07 | 8.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/30/2026 | -11.0% | -4.0% | |
| 11/13/2025 | -7.2% | -11.3% | 17.9% |
| 8/14/2025 | 15.8% | 11.5% | -7.3% |
| 3/31/2025 | -34.9% | -37.1% | -6.7% |
| 11/14/2024 | -7.0% | 2.5% | 90.1% |
| 8/14/2024 | 4.1% | 65.3% | 62.4% |
| 4/15/2024 | -5.7% | -18.2% | -53.9% |
| 11/14/2023 | -8.8% | -18.7% | -30.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 4 | 5 | 8 |
| # Negative | 12 | 11 | 7 |
| Median Positive | 4.4% | 11.5% | 37.5% |
| Median Negative | -8.2% | -10.3% | -19.0% |
| Max Positive | 15.8% | 65.3% | 167.1% |
| Max Negative | -34.9% | -37.1% | -53.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/03/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 04/15/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/30/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2027 Cash Runway | |||||||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.